vs

Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $17.1M, roughly 1.1× FREQUENCY ELECTRONICS INC). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -177.4%, a 187.9% gap on every dollar of revenue. On growth, FREQUENCY ELECTRONICS INC posted the faster year-over-year revenue change (8.3% vs -11.5%). FREQUENCY ELECTRONICS INC produced more free cash flow last quarter ($-1.1M vs $-23.1M). Over the past eight quarters, FREQUENCY ELECTRONICS INC's revenue compounded faster (11.8% CAGR vs -12.2%).

Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FEIM vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.1× larger
LAB
$19.6M
$17.1M
FEIM
Growing faster (revenue YoY)
FEIM
FEIM
+19.7% gap
FEIM
8.3%
-11.5%
LAB
Higher net margin
FEIM
FEIM
187.9% more per $
FEIM
10.5%
-177.4%
LAB
More free cash flow
FEIM
FEIM
$22.0M more FCF
FEIM
$-1.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FEIM
FEIM
Annualised
FEIM
11.8%
-12.2%
LAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
FEIM
FEIM
LAB
LAB
Revenue
$17.1M
$19.6M
Net Profit
$1.8M
$-34.7M
Gross Margin
38.2%
48.5%
Operating Margin
10.0%
-168.5%
Net Margin
10.5%
-177.4%
Revenue YoY
8.3%
-11.5%
Net Profit YoY
-32.1%
-28.8%
EPS (diluted)
$0.18
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FEIM
FEIM
LAB
LAB
Q4 25
$17.1M
Q3 25
$13.8M
$19.6M
Q2 25
$20.0M
$21.8M
Q1 25
$18.9M
$40.8M
Q4 24
$15.8M
Q3 24
$15.1M
$22.1M
Q2 24
$15.6M
$22.5M
Q1 24
$13.7M
$45.5M
Net Profit
FEIM
FEIM
LAB
LAB
Q4 25
$1.8M
Q3 25
$634.0K
$-34.7M
Q2 25
$3.2M
$-33.5M
Q1 25
$15.4M
$-26.0M
Q4 24
$2.7M
Q3 24
$2.4M
$-26.9M
Q2 24
$2.6M
$-45.7M
Q1 24
$130.0K
$-32.2M
Gross Margin
FEIM
FEIM
LAB
LAB
Q4 25
38.2%
Q3 25
36.8%
48.5%
Q2 25
37.5%
48.8%
Q1 25
43.8%
48.4%
Q4 24
48.2%
Q3 24
44.4%
54.9%
Q2 24
40.3%
46.1%
Q1 24
22.6%
53.1%
Operating Margin
FEIM
FEIM
LAB
LAB
Q4 25
10.0%
Q3 25
2.6%
-168.5%
Q2 25
16.4%
-118.1%
Q1 25
18.3%
-80.8%
Q4 24
16.5%
Q3 24
15.7%
-120.9%
Q2 24
16.0%
-134.5%
Q1 24
-3.4%
-132.2%
Net Margin
FEIM
FEIM
LAB
LAB
Q4 25
10.5%
Q3 25
4.6%
-177.4%
Q2 25
16.0%
-153.7%
Q1 25
81.4%
-63.8%
Q4 24
16.8%
Q3 24
16.1%
-122.0%
Q2 24
16.9%
-203.3%
Q1 24
0.9%
-70.6%
EPS (diluted)
FEIM
FEIM
LAB
LAB
Q4 25
$0.18
Q3 25
$0.07
$-0.09
Q2 25
$0.33
$-0.09
Q1 25
$1.60
$-0.07
Q4 24
$0.28
Q3 24
$0.25
$-0.07
Q2 24
$0.28
$-0.12
Q1 24
$0.01
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FEIM
FEIM
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$3.0M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$58.5M
$399.7M
Total Assets
$92.3M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FEIM
FEIM
LAB
LAB
Q4 25
$3.0M
Q3 25
$4.5M
$129.4M
Q2 25
$4.7M
$158.6M
Q1 25
$5.5M
$150.9M
Q4 24
$9.7M
Q3 24
$16.2M
$210.6M
Q2 24
$18.3M
$269.8M
Q1 24
$11.7M
$287.1M
Total Debt
FEIM
FEIM
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
FEIM
FEIM
LAB
LAB
Q4 25
$58.5M
Q3 25
$56.3M
$399.7M
Q2 25
$55.6M
$424.5M
Q1 25
$51.8M
$454.6M
Q4 24
$36.2M
Q3 24
$33.2M
$489.3M
Q2 24
$39.8M
$510.3M
Q1 24
$36.7M
$577.3M
Total Assets
FEIM
FEIM
LAB
LAB
Q4 25
$92.3M
Q3 25
$93.2M
$539.6M
Q2 25
$93.7M
$557.0M
Q1 25
$86.4M
$579.6M
Q4 24
$77.8M
Q3 24
$84.3M
$681.5M
Q2 24
$83.3M
$708.7M
Q1 24
$77.7M
$777.7M
Debt / Equity
FEIM
FEIM
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FEIM
FEIM
LAB
LAB
Operating Cash FlowLast quarter
$-523.0K
$-22.2M
Free Cash FlowOCF − Capex
$-1.1M
$-23.1M
FCF MarginFCF / Revenue
-6.6%
-118.1%
Capex IntensityCapex / Revenue
3.6%
4.5%
Cash ConversionOCF / Net Profit
-0.29×
TTM Free Cash FlowTrailing 4 quarters
$-5.5M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FEIM
FEIM
LAB
LAB
Q4 25
$-523.0K
Q3 25
$1.2M
$-22.2M
Q2 25
$-155.0K
$-20.7M
Q1 25
$-3.6M
$-30.3M
Q4 24
$3.8M
Q3 24
$-1.5M
$-27.9M
Q2 24
$7.5M
$-39.0M
Q1 24
$4.2M
$-62.5M
Free Cash Flow
FEIM
FEIM
LAB
LAB
Q4 25
$-1.1M
Q3 25
$385.0K
$-23.1M
Q2 25
$-786.0K
$-22.6M
Q1 25
$-4.0M
$-35.3M
Q4 24
$3.3M
Q3 24
$-1.8M
$-30.1M
Q2 24
$6.7M
$-41.0M
Q1 24
$3.9M
$-63.3M
FCF Margin
FEIM
FEIM
LAB
LAB
Q4 25
-6.6%
Q3 25
2.8%
-118.1%
Q2 25
-3.9%
-103.6%
Q1 25
-20.9%
-86.6%
Q4 24
20.8%
Q3 24
-11.8%
-136.4%
Q2 24
42.8%
-182.2%
Q1 24
28.4%
-138.9%
Capex Intensity
FEIM
FEIM
LAB
LAB
Q4 25
3.6%
Q3 25
5.6%
4.5%
Q2 25
3.2%
8.7%
Q1 25
1.7%
12.4%
Q4 24
3.3%
Q3 24
2.2%
10.2%
Q2 24
5.3%
8.6%
Q1 24
2.3%
1.7%
Cash Conversion
FEIM
FEIM
LAB
LAB
Q4 25
-0.29×
Q3 25
1.83×
Q2 25
-0.05×
Q1 25
-0.24×
Q4 24
1.44×
Q3 24
-0.60×
Q2 24
2.85×
Q1 24
32.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FEIM
FEIM

POC Revenue$14.8M86%
POT Revenue$2.3M13%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons